Applied Therapeutics, Inc. (APLT)

Market Cap	41.81M
Revenue (ttm)	n/a
Net Income (ttm)	-95.24M
Shares Out	48.00M
EPS (ttm)	-4.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,279
Open	0.85
Previous Close	0.87
Day's Range	0.8 - 0.864
52-Week Range	0.5 - 10.34
Beta	1.65
Analysts	Buy
Price Target	11.73 (+1,287.5%)
Earnings Date	Nov 11, 2022

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III c...

• Industry: Biotechnology
• IPO Date: May 14, 2019
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: APLT

Analyst Forecast

According to 11 analysts, the average rating for APLT stock is "Buy." The 12-month stock price forecast is 11.73, which is an increase of 1,287.51% from the latest price.

Price Target

$11.73

(1,287.51% upside)

Analyst Consensus: Buy